secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2021-12-15T23:59:59+00:00
Accession:  0001104659-21-149776
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora Pharmaceuticals appoints David Hollander, MD, MBA to its Board of Directors
--------------------------------------------------------------------------------

- Appointment effective December 13, 2021; press release issued December 15, 2021.
- Hollander is Chief R&D Officer at Aerie Pharmaceuticals, with extensive ophthalmic industry experience.
- He fills a vacancy created by board resignations in August 2021.
- Will serve as Class III director until 2024 Annual Meeting of Stockholders.
- Board determined he is independent under Nasdaq Capital Market rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000110465921149776/0001104659-21-149776-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000110465921149776/tm2135455d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-149776

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer